Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan

References

• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733–40.
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722–9.
   PubMed Web of Science ®Google Scholar
• Henriksson R, Asklund T, Poulsen HS. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol 2011;104:639–46.
   PubMed Web of Science ®Google Scholar
• Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol 2009;48:52–8.
   PubMed Web of Science ®Google Scholar
• Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13:143–51.
   PubMed Web of Science ®Google Scholar
• Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014;15:943–53.
   PubMed Web of Science ®Google Scholar
• Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 2007;25:2601–6.
   PubMed Web of Science ®Google Scholar
• Gorlia T, Stupp R, Brandes AA, Rampling RR, Fumoleau P, Dittrich C, et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer 2012;48:1176–84.
   PubMed Web of Science ®Google Scholar
• Chen C, Huang R, Maclean A, Muzikansky A, Mukundan S, Wen PY, et al. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol 2013;115:267–76.
   PubMed Web of Science ®Google Scholar
• Duerinck J, Clement PM, Bouttens F, Andre C, Neyns B, Staelens Y, et al. Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma. J Neurol 2015;262: 742–51.
   PubMed Web of Science ®Google Scholar
• Tabouret E, Barrie M, Thiebaut A, Matta M, Boucard C, Autran D, et al. Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen. J Neurooncol 2013;114:191–8.
   PubMed Web of Science ®Google Scholar
• Dahlrot RH, Kristensen BW, Hjelmborg J, Herrstedt J, Hansen S. A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1. Int J Clin Exp Pathol 2013;6:31–40.
   PubMed Web of Science ®Google Scholar
• Macdonald DR, Cascino TL, Schold SC JrJr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–80.
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963–72.
   PubMed Web of Science ®Google Scholar
• Harrell FE JrJr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15: 361–87.
   PubMed Web of Science ®Google Scholar
• Watling CJ, Lee DH, Macdonald DR, Cairncross JG. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 1994;12:1886–9.
   PubMed Web of Science ®Google Scholar
• Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 2000;18:646–50.
   PubMed Web of Science ®Google Scholar